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Abstract
Human ESC and iPSC are an attractive source of cells of high quantity and purity to be used to elucidate early human
development processes, for drug discovery, and in clinical cell therapy applications. To efficiently differentiate pluripotent
cells into a pure population of hematopoietic progenitors we have developed a new 2-dimentional, defined and highly
efficient protocol that avoids the use of feeder cells, serum or embryoid body formation. Here we showed that a single
matrix protein in combination with growth factors and a hypoxic environment is sufficient to generate from pluripotent
cells hematopoietic progenitors capable of differentiating further in mature cell types of different lineages of the blood
system. We tested the differentiation method using hESCs and 9 iPSC lines generated from different tissues. These data
indicate the robustness of the protocol providing a valuable tool for the generation of clinical-grade hematopoietic cells
from pluripotent cells.
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Introduction
Human embryonic stem cells (hESCs) and human induced
pluripotent stem cells (hiPSCs) have the ability to proliferate
indefinitely in an undifferentiated state, and to differentiate to
virtually all mature cell types found in the human body when
induced with the appropriate combination of growth factors and
cytokines. Pluripotent cells offer a powerful system to create in vitro
models of human development and disease, provide a valuable
source of large quantities of mature cell types of consistent quality
and purity for drug discovery and testing, and have strong
potential for clinical cell replacement therapies. The hematopoi-
etic system is of particular interest for these applications due to the
wide range of progenitor and mature blood cell types, which could
be generated from pluripotent cells, and for the already available
large amount of information on the development and character-
ization of these cells. Moreover, establishing a protocol to induce
differentiation of hESCs into hematopoietic progenitors provides
an easy approach to access to initial steps of hematopoiesis during
human ontogeny, which occur in the first weeks of the developing
embryo and are therefore impractical to study in vivo. Finally, a
robust differentiation method together with the accessibility of
patient-specific pluripotent cell lines provide a novel approach to
study blood disorders [1], and generation of patient-specific
multipotent hematopoietic progenitors could eventually be used in
cellular therapy.
Despite the differentiation method used, in vitro hematopoietic
differentiation from pluripotent cells (hESCs or hiPSCs) seems to
progress through the same stages of hematopoietic development in
vivo: during the initial week the differentiating hESC cultures are
characterized by the presence of hemato-endothelial progenitors
(hemangioblast) [2,3–5]. This initial developmental stage in vitro
appears to resemble the yolk-sac phase of hematopoiesis in vivo,
when hematopoietic progenitors have the potential to give rise to
primitive erythroid cells, megakaryocytes and macrophages. Only
with an extended differentiation time are hematopoietic progen-
itors capable of maturing further, and therefore acquiring a
broader developmental potential. However, current methods for
hematopoietic differentiation of pluripotent stem cells rely on the
use of serum, co-culture on stromal cell lines or the formation of
embryoid bodies (EB) [2,3,6–12]. The poorly defined factors
present in bovine serum, as well as in conditions when feeder cells
are used, and the high variability of the embryoid body system
prompted us to develop a new, defined, animal product-free
differentiation system to generate clinical grade hematopoietic
progenitors easily applicable to test the effect of small molecules in
large scale screens. In the present study, we describe a novel 2-
dimentional (2D), feeder-free, serum-free, highly efficient differ-
entiation system for generating hematopoietic progenitors from
hESCs. Our data also show the robustness of our protocol, as it
induced the same pattern of hematopoietic differentiation
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somatic cell types. In summary, a single matrix protein is sufficient
to support hematopoietic differentiation using a cocktail of growth
factors and hypoxic conditions that resemble the environment in
the developing embryo.
Results
Effect of matrix proteins and oxygen concentration on
hESC-derived hematopoietic progenitor development
To establish a completely defined 2D hematopoietic differen-
tiation method, we tested the ability of matrix support proteins and
altered atmospheric conditions to promote serum–free hemato-
poietic and endothelial differentiation from hESCs induced by a
cocktail of growth factors (BMP-4, VEGF and bFGF) already
shown to support hemato-endothelial differentiation from hESCs
grown on MEFs (mouse embryonic fibroblasts) [13]. A schematic
diagram of the differentiation protocol used in this study is
depicted in Fig. 1A. We selected human fibronectin and collagen
IV as matrix proteins because they are known to support
hematopoietic differentiation of ESC-derived Flk1 progenitors in
the mouse system [14]. Fibronectin has been implicated in the
progression of mesodermal differentiation [15] and is commonly
used to induce endothelial differentiation from endothelial
progenitors (HUVEC or hESC-derived). Collagen IV has been
reported to promote mesoderm development, as it has been used
to induce endothelial, cardiovascular and hematopoietic differen-
tiation from murine ESCs [16,17], from murine iPSCs [18] and
from human ESCs [19].
To mimic the environment in the growing embryo at the stage
when hemato-endothelial progenitors start to develop, we
examined the role of hypoxia (5% O2 tension) during hematopoi-
etic commitment to reflect more physiological oxygen levels.
Hypoxia has been shown to have an important role in vivo in the
very early stages of the growing embryo [20]. Before the
establishment of the cardiovascular system, mammalian develop-
ment occurs in a 3% oxygen environment. This physiological
hypoxia seems to be an important regulator of embryonic
angiogenesis and hematopoiesis. Among other effects, this low
oxygen concentration induces expression of genes (such as FLK1,
BMP-4 and VEGF) and stimulation of pathways (hypoxia
inducible factor, HIF-dependent pathways) required for the
formation and proliferation of the hemato-endothelial progenitors
[21–23]. Moreover, hypoxia has already been shown to promote
endothelial differentiation from hESCs [24]. The presence of
hematopoietic progenitors was evaluated after 6 days of differen-
tiation by the expression of CD43, the earliest hematopoietic-
specific marker shown to appear in the hESCs/OP9 co-culture
differentiation system [5].
As shown in Fig. 1C, both matrix proteins favored the
attachment of the hESCs and the subsequent hematopoietic
differentiation, with a significantly higher number of hematopoi-
etic cells generated on collagen IV, as compared to fibronectin at
day 6. On both matrix proteins we observed an increased and
more consistent efficiency of hematopoietic progenitor generation
in hypoxic cultures, which was therefore the condition of choice
for the following experiments. Since murine collagen IV promoted
hematopoietic differentiation as efficiently as the human counter-
part, all subsequent studies were performed using murine collagen
IV. In order to have a completely defined protocol for generating
hematopoietic progenitors, we tested two serum substitutes,
containing human serum albumin, human recombinant insulin
and human transferrin (HIT and Serum Replacement 3). In
hypoxic conditions, both reagents sustained hematopoietic and
Figure 1. Optimization of the 2D differentiation protocol for
hematopoietic differentiation. (A) The 2D differentiation protocol.
Pluripotent stem cells (PSC) grown as colonies (in orange) on Matrigel
(in blue) are dissociated and plated on a matrix protein (fibronectin or
collagen IV, in green). After 24 hrs growth factors are added to the
medium to induce hematopoietic progenitor cell (HPC, in yellow)
development. The growth factor cocktail is change after 6 days of
differentiation. (B) Cell morphology during the differentiation of
pluripotent stem cells. After 6 days of differentiation, cells remain
adherent, but change in morphology. Only after 10 days of
differentiation do some colonies of round, loosely attached cells start
to appear (arrow). After 14 days of differentiation many round, loosely
attached cells cover the dish on top of a layer of adherent cells. (C)
Percentage of CD43
+ cells after 6 days of differentiation on different
matrix proteins. Standard errors are indicated (Hypoxia in blue: n=20
on hFibronectin, n=3 on hCollagen IV, n=27 on mCollagen IV;
Normoxia in red: n=5 on hFibronectin, n=1 on mCollagen IV).
Statistically significant difference between hFibronectin and mCollagen
IV is indicated with a star (*) p,0.005. The yield of CD43
+ cells (in green)
is calculated as total number of CD43
+ cells generated per each hESC
induced to differentiate under hypoxic conditions.
doi:10.1371/journal.pone.0017829.g001
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assessed by the presence of CD43
+CD34
+ hematopoietic progen-
itors and CD31
+CD34
+CD43
2 endothelial cells after 6 days of
differentiation (data not shown).
Characterization of the hESC-derived hematopoietic
progenitors
After 6 days the CD34 progenitor marker appeared on up to
40% of the hESCs differentiating on collagen IV under hypoxic
conditions using serum-free substitutes (Fig. 2A). Early CD34
+ cells
are a heterogeneous population consisting of hematopoietic,
endothelial and mesenchymal progenitor cells [8]. In our 2D
culture system, after 6 days of differentiation almost every hESC
generated one CD34
+CD43
+ hematopoietic progenitor (Fig. 2D).
This population of CD34
+CD43
+ hematopoietic progenitors
represented more than half of the CD34
+ cells and 25% of the
total culture (Fig. 2A). The optimized culture conditions also
favored the generation of CD34
+CD31
+CD43
2 endothelial
progenitors (up to 50% of cells at day 6), consistent with the
hemato-endothelial development in the early stages of hemato-
poiesis in the embryo. HESC-derived progenitors harvested after 6
days of differentiation gave rise to pink-colored erythroid colonies
in serum-free methylcellulose-based colony assays (Fig. 2B). At this
developmental stage, hematopoietic cells (CD43
+) express the
progenitor marker CD34 and the erythroid lineage marker
CD235a (GlycophorinA) (Fig. 2A). Although we could not detect
CD41a, a megakaryocyte marker, in these early differentiating
cultures at day 6, these progenitor cells were able to generate
megakaryocyte colonies in collagen-based colony assays (Fig. 2B),
suggesting the presence of erythro-megakaryocyte progenitors, as
it has been previously shown in the OP9 co-culture system [25].
Prolonging the differentiation resulted in the appearance of
loosely attached, hematopoietic progenitor cells at around day 10
of differentiation (Fig. 1B). Collection of the floating cells in the
culture resulted in an almost pure hematopoietic population
consisting of 90% CD43
+ cells (Fig. 2A), with average yield of
three hematopoietic cells generated per hESC (Fig. 2D). Although
the majority of these cells still consisted of erythro-megakaryocytic
progenitors (80% of the CD43
+ cells are CD235a
+CD41a
+/2), the
pan-hematopoietic marker CD45 started to be expressed together
with CD34 and CD43 (7% of the culture). CD34
+CD43
+CD45
+ is
a phenotypical signature for hematopoietic multipotent progeni-
tors, as confirmed in methylcellulose-based colony assay where
these cells were able to give rise to CFC-E, CFC-M, CFC-GM and
mixed colonies, typical of multipotent hematopoietic progenitors
(Fig. 2B, C). Extending the differentiation for 4 days expanded the
CD45
+ cells which represented 35% of the floating cells (Fig. 2A).
At the end of this protocol the total yield of the CD45
+ subset was
of one CD45
+ cell generated per hESC induced to differentiate
(Fig. 2D). The multiple developmental potential of these cells was
also confirmed in further differentiation cultures to mature cell
types. Using different combinations of growth factors, from the
hESCs-derived progenitor cells we were able to obtain
CD71
+CD235a
+ erythroid cells, CD41a
+CD42b
+ megakaryo-
cytes, HLA-DR
+CD1a
+ dendritic cells, CD14
+CD68
+ macro-
phages, CD45
+CD117
+ expressing tryptase mast cells and
CD15
+CD66B
+ neutrophils (Fig. 3).
Hematopoietic differentiation from 9 hiPSC lines
generated from different tissues
The optimized 2D hematopoietic differentiation was tested on
several hiPSC lines. The hiPSC lines were generated with viral
transduction of human mature cells of different tissue origin: two
lines were generated from human fetal fibroblasts (FFiPSC); two
lines were generated from CD34
+ PBMCs collected from a donor
leukocyte pack (BliPSC); two lines were generated from keratino-
cytes isolated from primary human keratinocytes (KiPSC); one line
was generated from adult skin fibroblast (SiPSC); two lines were
generated from T-cells isolated from a donor leukocyte pack
(TiPSC) [26]. We used the differentiation protocol optimized to
achieve the maximum yield from the hESC line as standard
conditions to compare all the hiPSC lines. After 6 days of
differentiation we detected CD34
+CD43
+ hematopoietic and
CD31
+CD43
2 endothelial progenitors from all iPSC lines
(Fig. 4A). Similar to hESC-derived progenitors, hiPSC-derived
hematopoietic progenitors harvested at day 6 appeared to be
restricted to the erythroid lineage for the presence of the erythroid
marker CD235a on the cell surface. These progenitors could
generate megakaryocytes in colony assays as well as in culture,
when induced with defined factors (Fig. 4B). For all the hiPSC
lines, prolonging differentiation for 8 more days resulted in further
development of the hematopoietic progenitors, which started to
express CD45 while still retaining CD34 expression (Fig. 4A). The
floating iPSC-derived hematopoietic progenitors were able to
differentiate further into several lineages (Fig. S1) similarly to the
hESC-derived progenitors. Despite the successful hematopoietic
differentiation from all nine different hiPSC lines, we observed a
high variability in differentiation efficiency. Variability in the
efficiency of hematopoietic progenitor differentiation has been
reported in an analogous analysis performed on different hiPSC
lines using the OP9 co-culture system [11]. We could not observe
any correlation between the hematopoietic differentiation efficien-
cy and the cell origin of each hiPSC line. These differences might
be either the result of viral integration in each clone, or simply an
intrinsic variability among the lines, that has also been observed
among hESC lines [11] and among iPSCs of murine origin [27].
We can therefore conclude that under the optimized condition for
hematopoietic differentiation, we did not observe consistent
differences between hESC and iPSC groups.
Discussion
The present work outlines an efficient and directed differenti-
ation method to generate hematopoietic progenitors from human
pluripotent cells using a 2D, feeder-free, serum-free, completely
defined system. For potential clinical applications of cells
generated with the described method, we show that our system
can be easily converted to xenogenic-free conditions, as the only
reagents of non-human origin used for our differentiation protocol
are the bFgf of zebrafish origin in the differentiation medium, and
bovine serum albumin in serum replacer and in the pluripotent
cell growth medium (mTeSR1), which can be substituted with the
human counterparts. Other 2D methods shown to support
hemato-endothelial differentiation include the use of mouse
embryonic fibroblasts [13], bone marrow stromal cells, such as
S17, MS-5 or OP9, [7,8], or cells derived from fetal liver or AGM
region of murine embryos [28]. The overall differentiation
efficiency of these methods is quite low considering the fraction
of CD34
+ multipotent cells obtained in the culture (0.9%–20%),
and even lower if the hematopoietic progenitors expressing CD45
are considered (0.1%–8%) during 7–20 days of differentiation.
The only report on the use of collagen IV to sustain hematopoietic
differentiation from hESCs does not provide information on the
efficiency of the method, since the progenitors were not quantified
[19]. The present protocol is completely defined and generates
hematopoietic and endothelial cells at very high efficiency. The
hypoxic conditions improved the percentage of hematopoietic cells
Hematopoietic Differentiation of Human Stem Cells
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matrix support proteins. Following 6 days of differentiation up to
40% of the cells expressed CD34 and up to 25% expressed CD43,
generated with an average yield of one progenitor per hESC. After
two weeks of differentiation we could isolate a large number of
floating hematopoietic progenitor cells, of which 90% were CD43
+
cells still retaining the CD34 marker and starting to express CD45
on their surface. Prolongation of the differentiation time also
increased the yield of hematopoietic progenitors. We could show
that this population of cells is able to differentiate further into
mature cells of different lineages when specific growth factors for
each lineage were added to the culture medium. Among the
mature cell types we obtained using this method, of particular
interest is the generation of megakaryocytes. To date, in vitro
generation of megakaryocytes from human pluripotent cells has
been largely achieved from somatic stem cells (bone marrow, or
cord blood or mobilized peripheral blood CD34
+ cells [29–35]).
Recently, three groups have reported megakaryocyte differentia-
tion from hESC lines using the murine OP9 co-culture system
[25,36,37] and one group using the EB method [38]. Our work
presents, therefore, for the first time a protocol devoid of serum
and other undefined conditions to obtain megakaryocytes from
hESCs and hiPCSs capable of shedding platelets in vitro. Obtaining
large quantities of megakaryocytes in vitro could offer a valuable
example of using hESC/hiPSC-derived cells to study disorders
affecting a rare population of cells (megakaryocyte represent 0.1%
of the nucleated cells in the bone marrow), but most importantly
could set the stage for the production of a cell type, which could be
used in clinical settings. It has been proposed that co-transplan-
tation of autologous megakaryocytes together with hematopoietic
stem cells could result in higher response and survival rates for
patients afflicted by the severe thrombocytopenia often associated
with high dose chemotherapy and radiation therapy [39]. The
advantage of using autologous cells in transplantation studies
prompted us to test our protocol on nine hiPSC lines generated in
our laboratories using retroviral transduction of cells of different
tissue origin. HiPSCs have already been shown to be able to
differentiate into various lineages, such as cardiac [40], pancreatic
[41], hepatic [42], epithelial [6,43,44], neuronal [45–47], adipose
[48], and endothelial and hematopoietic [6,11,49–51]. The fast
pace of basic research on hiPSCs since their discovery in 2007
[52,53] reflects the high value of these new pluripotent lines for
drug testing, preclinical models and clinical application. For the
potential use of hiPSCs in pre- and clinical settings the major
challenge is to define culture conditions to differentiate progenitor
cells into a selected lineage with high efficiency and purity. Here
we tested several hiPSC lines generated by our group for their
ability to differentiate into hematopoietic progenitors using the 2D
protocol optimized on a hESC line. Despite some expected
differences in differentiation efficiency, we were able to generate
hematopoietic progenitors from nine hiPSC lines derived from 5
different tissue types. As proof of principle we generated
megakaryocytes from fibroblast (FFiPSC)-derived iPSCs with the
same efficiency and characteristics as hESC-derived megakaryo-
cytes. There are no previous reports in the literature to show the
megakaryocyte potential of hiPSCs and the production of platelet-
releasing megakaryocytes in vitro. The hiPSC-derived hematopoi-
etic progenitors also had the potential to develop to cell types of
other lineages of the blood system, such as erythroid cells,
macrophages and dendritic cells. In our system we did not detect a
lack of hematopoietic potential in iPSC lines generated from
reprogrammed fibroblasts as it has been observed in [54], possibly
due to an erase of the epigenetic memory as a consequence of
prolonged culture in vitro as it has been suggested in [55].We can
therefore conclude that, although further optimization for each
hiPSC line seems to be required to achieve a maxim yield of
hematopoietic differentiation from each line, hiPSCs and hESCs
exhibit the same developmental potential in vitro.
In conclusion, we propose here a highly efficient new system to
generate in vitro hematopoietic progenitors from hESCs and
hiPSCs in conditions free of animal products and undefined
components, which is easily applicable in basic research, drug
discovery testing and clinical settings.
Materials and Methods
Pluripotent stem cell cultures
hESCs H1 (WA01) were obtained from WiCell Research
Institute and different hiPSC lines were generated in house by
retroviral expression of OCT4/SOX2/KLF4/MYC or OCT4/
SOX2/Lin28/Nanog in different donor tissue samples as
described elsewhere (patent application n. 20100041054 published
on Feb. 18, 2010). The pluripotent stem cells were maintained in
colonies on Matrigel (BD)- coated plates in mTeSR1 (BD) and
dissociated with dispase (Invitrogen) as described in [56]. HESC
H1 line was used within 33 to 53 passage numbers. FFiPSC lines
were used within 30 to 40 passage numbers. BliPSC lines were
used within 12 to 30 passage numbers. KiPSC lines were used
within 20 to 30 passage numbers. SiPSC line was used within 40 to
50 passage numbers. TiPSC lines were used within 10 to 30
passage numbers. Cells were grown in 5% CO2 and regular
atmospheric O2 concentration.
Differentiation of hESC/hiPSCs
The protocol of hematopoietic differentiation from hESC/
hiPSCs was established during the development of iCell
TM
endothelial cells (Cellular Dynamics International, Inc.). To initiate
hematopoietic differentiation, hESC/hiPSCs grown on matrigel
were dissociated with TrypLe (Gibco, Invitrogen) and transferred at
20,000 cells/cm
2 onto 6-well plates pre-coated with 3 mg/cm
2
human plasma fibronectin (Gibco, Invitrogen) or murine collagen
IV (BD) in mTeSR1 medium (Stem Cell Technologies) supple-
mented with soybean trypsin inhibitor (Invitrogen) and an inhibitor
of Rho-associated kinase (ROCK) as survival factor (H1152,
Figure 2. Characterization of the hESC-derived hematopoietic progenitors. (A) FACS analysis of differentiated cells at day 6 (total culture),
at day 10 (only floating cells analyzed) and at day 14 (only floating cells analyzed). Representative FACS plots are indicated, showing live- and CD34
+-
gated events for CD43
+CD31
+ cells at day 6, and live-gated events for all the other plots. (B–C) Colony assays of hESC-derived hematopoietic
progenitors harvested after 6 days (total culture) and after 10 or 14 days (floating cells) of differentiation. In methylcellulose-based assay (MethoCult),
day 6 hESC-derived progenitors generated salmon-pink erythroid colonies; floating hESC-derived progenitors generated CFC-GM, CFC-M, CFC-E and
mixed colonies. Average CFC values per 10
5 cells 6 standard errors: Day 6 N=9 CFC-E 84.69632.33, CFC-M 7.6862.54, CFC-GM 1.4960.93, mixed
1.5860.32; Day 10 N=5 CFC-E 208.88675.59, CFC-M 26611.90, CFC-GM 2.8861.97, mixed 3.5260.75; Day 14 N=8 CFC-E 117.33652.40, CFC-M
72.63620.28, CFC-GM 13.2864.36, mixed 2.560.98. In collagen-based assay (MegaCult), hESC-derived progenitors developed large colonies of
megakaryocytes capable of shedding pro-platelets (arrow). (D) Yield of hematopoietic cell subsets obtained per one differentiating hESC at day 6 (in
blue), day 10 (in red) or day 14 (in green). Standard errors are indicated (CD43
+ cells: at day 6 N=23, at day 10 N=11, at day 14 N=16; CD43
+CD34
+
cells: at day 6 N=18, at day 10 N=8, at day 14 N=16; CD45
+ cells: N=23, at day 10 N=6, at day 14 N=11).
doi:10.1371/journal.pone.0017829.g002
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differentiation medium containing IMDM (Invitrogen), BIT (bovin
serum albumin, human recombinant insulin, human transferrin,
Stem Cell Technologies), monothioglycerol (450 mM, Sigma), non
essential aminoacids (0.1 mM, Invitrogen), L-glutamine (2 mM,
Invitrogen), recombinant human BMP4 (50 ng/ml, R&D), recom-
binant human VEGF (50 ng/ml, Invitrogen) and recombinant
zebrafish bFGF (50 ng/ml) made in house. For the humanized
version we substituted BIT with HIT (Stem Cell Technologies) or
Serum Replacer 3 (Sigma). After 6 days of culture the cells are
dissociated withTrypLe andanalyzed byflowcytometry.To extend
the hematopoietic differentiation, after one week the cytokine
cocktail in the differentiation medium changed to a medium
containing heparin (5 U/ml, Sigma), TPO (25 ng/ml), human
recombinant SCF (25 ng/ml), FLT3L (25ng/ml), IL-3 (10ng/ml),
IL-6 (10ng/ml), all from Invitrogen. At day 10 or 14 the floating
cells were harvested and analyzed using flow cytometry and colony
forming assays using methylcellulose-based serum-free medium
(MethoCult H4436, Stem Cell Technologies) and collagen-based
megakaryocyte colony assay (MegaCult, Stem Cell Technologies)
Figure 3. Characterization of the developmental potential of hESC-derived hematopoietic progenitors. FACS analysis and
corresponding cytospins of mature cells generated in culture from hESC-derived progenitors induced with defined factors. Images were taken at
406magnification. Cytospins of erythroid cells, dendritic cells, macrophages and neutrophils were stained with Wright. Cytospins of megakaryocytes
were stained for GPIIb/IIIa (CD41a). Cytospins of mast cells were stained for tryptase. The yield hESC:mature cell indicates the number of each mature
cell type generated per each hESC induced to differentiate.
doi:10.1371/journal.pone.0017829.g003
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performed in hypoxic conditions (5% O2 concentration, balanced
with nitrogen).
Differentiation of hematopoietic progenitors into mature
cell type
Erythroid cells: Cells harvested after 6 days of differentiation
were transferred in low attachment plates to a medium containing
SFEM (Stem Cell Technologies), heparin (5 U/ml, Sigma), TPO
(100 ng/ml), human recombinant SCF (100 ng/ml), FLT3L
(100 ng/ml), IL-3 (10 ng/ml), IL-6 (10 ng/ml), all from Invitro-
gen. After 4 days erythroid cells were expanded in SFEM medium
containing 0.3% Excyte (Serologicals), Holo-Transferrin (1 mg/
ml, Sigma), Hydrocortisone (1mM, Sigma), Insulin (20 ng/ml,
Sigma), SCF (50 ng/ml, R&D Systems), EPO (2 U/ml, R&D
Systems), IL-3 (5 ng/ml), IL-6 (10 ng/ml) and TPO (50 ng/ml,
Figure 4. Characterization of the developmental potential of 9 hiPSC lines generated from different donor tissues. (A) Percentage of
positive cells for the indicated marker in the differentiating culture. Total culture at day 6 of differentiation, or floating cells at day 14 were analyzed.
Standard errors are indicated (n=10 H1, n=3 FFiPSC 6.6, n=2 FFiPSC 6.1, n=3 BliPSC CK, n=4 BliPSC NL, n=2 KiPSC2, n=3 KiPSC5, n=6 SiPSC, n=2
TiPSC 1b, n=3 TiPSC 1ee). (B) FFiPSC 6.1-derived hematopoietic progenitors isolated at day 10 of differentiation generated CD41a
+CD42b
+
megakaryocytes in culture, as indicated by flow cytometry analysis, cytospins stained for GPIIb/IIIa (CD41a), and megakaryocytes colonies in collagen-
based assay. The megakaryocytes were able to produce pro-platelets (arrow) visible both in culture and in collagen-based colony assay.
doi:10.1371/journal.pone.0017829.g004
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TPO were removed from the medium and the cells cultured for
one week, then analyzed by flow cytometry for the expression of
CD235a (glycophorin A) and CD71.
Megakaryocytes: Cells harvested at days 6, 10, or 14 of
differentiation were transferred to low attachment plates in
medium containing SFEM (Stem Cell Technologies), heparin
(5 U/ml, Sigma), TPO (100 ng/ml), human recombinant SCF
(100 ng/ml), FLT3L (100 ng/ml), IL-3 (10 ng/ml), IL-6 (10 ng/
ml). After 10 days of culture the presence of megakaryocytes was
assessed by FACS for the expression of CD41a and CD42b and
cytospins of the culture were stained for GPIIb/IIIa (CD41a).
Dendritic cells: After 14 days of differentiation the floating
hematopoietic cells in suspension were collected and expanded for
a week in SFEM (Stem Cell Technologies), 1% Excyte
(Serologicals), monothioglycerol (450mM, Sigma), non essential
aminoacids (0.1 mM, Invitrogen), L-glutamine (2 mM, Invitro-
gen), GM-SCF (100 ng/mL, Leukine). The cells were then placed
in dendritic cell differentiation medium containing SFEM, 1%
Excyte, monothioglycerol (450mM, Sigma), non essential aminoa-
cids (0.1 mM, Invitrogen), L-glutamine (2 mM, Invitrogen), GM-
SCF (20 ng/mL), IL-4 (20 ng/ml, Peprotec), TNF-a (2.5 ng/mL,
Peprotec). After one week the presence of dendritic cells was
assessed by FACS for the expression of CD1a and HLA-DR.
Macrophages: After 14 days of differentiation the floating
hematopoietic cells in suspension were collected and expanded for
a week in SFEM (Stem Cell Technologies), 1% Excyte
(Serologicals), monothioglycerol (450mM, Sigma), non essential
aminoacids (0.1 mM, Invitrogen), L-glutamine (2 mM, Invitro-
gen), GM-SCF (100 ng/mL, Leukine). The cells were then
transferred to macrophage specific medium: SFEM (Stem Cell
Technologies), 1% Excyte (Serologicals), monothioglycerol
(450 mM, Sigma), non essential aminoacids (0.1 mM, Invitrogen),
L-glutamine (2 mM, Invitrogen), M-CSF (20 ng/mL, Peprotec),
IL-1b (10 ng/mL, Peprotec). After one week the presence of
macrophages was assessed by FACS for the expression of CD14
and CD68.
Mast cells: After 14 days of differentiation, cells were harvested
and cultured for 14 days in low attachment plates in medium
containing SFEM (Stem Cell Technologies), heparin (5 U/ml,
Sigma), TPO (100 ng/ml), human recombinant SCF (100 ng/ml),
FLT3L (100 ng/ml), IL-3 (10 ng/ml), IL-6 (10 ng/ml). Finally
cells were transferred in medium containing StemPro-34 (Invitro-
gen), non essential aminoacids (0.1 mM, Invitrogen), L-glutamine
(2 mM, Invitrogen), SCF (100 ng/ml, Invitrogen), IL-6 (100 ng/
ml, Invitrogen). Mast cells were analyzed by FACS after three
weeks in this last medium for the expression of CD117 and CD45,
and the cytospins stained for Tryptase.
Granulocytes: After 14 days of differentiation on collagen IV,
the cytokine cocktail was substituted with only G-CSF (100 ng/ml,
Invitrogen) and after one week the presence of neutrophils was
assessed by FACS for the expression of CD66B and CD15.
Flow cytometry and immunostaining
All FACS antibodies CD34 FITC, CD43 APC, CD43 FITC,
CD31 PE, CD235a PE, CD41a FITC, CD45 APC, CD71 FITC,
CD42b APC, HLA-DR PE, CD1a APC, CD14 APC, CD68 PE,
CD117 PE, CD66B FITC, CD15 APC were from BD Biosciences.
CD68 staining was performed after cell permeabilization with
Fix&Perm reagents (Caltag, Invitrogen). Cytospins of erythroid
cells, dendritic cells, macrophages and neutrophils were stained
with Wright (Protocol) according to manufacturer’s instructions.
Cytospins of megakaryocytes were stained for GPIIb/IIIa (CD41a)
according to manufacturer’s instructions of the MegaCult kit.
Cytospins of mast cells were stained for tryptase: the cytospin slides
were fixed in 1:3 methanol:acetone and stained overnight at 4uC
with 1.8 mg/ml anti-tryptase antibody clone G3 (Chemicon) in
TBS (pH=7.6) with 10% FBS. The next day, the slides were
brought to room temperature, washed with TBS, and slides were
incubated with polyclonal rabbit anti-mouse immunoglobulins
(Dako) for thirty minutes. After another wash, alkaline phospha-
tase anti-alkaline phosphatase (APAAP) reagent (Dako) was added
to the slides for thirty minutes. SigmaFAST (Fast Red TR/
Naphthol AS-MX/Levamisol) substrate tablets were used to
develop the reaction. Visible color developed on the slides after
approximately seven minutes, at which time the reaction was
stopped.
Supporting Information
Figure S1 Characterization of the developmental poten-
tial of one hiPSC line. FACS analysis of mature cells generated
in culture from BliPSC NL-derived progenitors induced with
defined factors.
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